U
ORMP icon

UBS’s Oramed Pharmaceuticals ORMP Stock Holding History

UBS’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-1,000
Closed -$10K – 10633
2014
Q2 		$10K Buy
1,000
+900
+900% +$9.19K ﹤0.01% 8891
2014
Q1 		$1K Buy
+100
New +$1.69K ﹤0.01% 10223

Other funds holding ORMP

AWMDMG
Austin W. Marxe & David M. Greenhouse New York $733M AUM 21.72% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
GIM
Greylin Investment Management Orange, Virginia $598M AUM 18.59% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CA
Commerzbank Aktiengesellschaft Frankfurt, Germany $4.78B AUM 25.31% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

UBS's ORMP Position: Q3 2014 in Review

UBS reduced its Oramed Pharmaceuticals (ORMP) stake by 6.1% in Q3 2014, selling an estimated $2.53K and leaving 4,387 shares worth $36K. The position accounts for ﹤0.01% of the portfolio, ranked #7227.

UBS first reported a position in ORMP in Q2 2013 and has held it in 6 quarters since. The position peaked at $45K in Q2 2014. 19 funds tracked by Wall St. Rank hold ORMP as of Q3 2014.

  • UBS held 4,387 shares of Oramed Pharmaceuticals worth $36K as of Q3 2014.
  • UBS sold 285 Oramed Pharmaceuticals shares in Q3 2014, an estimated $2.53K.
  • Oramed Pharmaceuticals made up ﹤0.01% of UBS's portfolio in Q3 2014, its #7227 holding.
  • UBS first reported a position in Oramed Pharmaceuticals in Q2 2013 and has held it in 6 quarters since.
  • UBS's Oramed Pharmaceuticals position peaked at $45K in Q2 2014.
  • 19 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.